BNP Paribas Financial Markets’s Insight Molecular Diagnostics IMDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $210 | Buy |
64
+34
| +113% | +$197 | ﹤0.01% | 5626 |
|
|
2025
Q4 | $225 | Hold |
30
| – | – | ﹤0.01% | 5557 |
|
|
2025
Q3 | $100 | Sell |
30
-208
| -87% | -$587 | ﹤0.01% | 5435 |
|
|
2025
Q2 | $719 | Buy |
238
+30
| +14% | +$91 | ﹤0.01% | 5185 |
|
|
2025
Q1 | $636 | Hold |
208
| – | – | ﹤0.01% | 5117 |
|
|
2024
Q4 | $495 | Buy |
+208
| New | +$565 | ﹤0.01% | 5174 |
|
|
2023
Q3 | – | Sell |
-208
| Closed | -$958 | – | 4006 |
|
|
2023
Q2 | $958 | Hold |
208
| – | – | ﹤0.01% | 3769 |
|
|
2023
Q1 | $1.48K | Sell |
208
-40
| -16% | -$297 | ﹤0.01% | 3657 |
|
|
2022
Q4 | $1.59K | Sell |
248
-65
| -21% | -$717 | ﹤0.01% | 3757 |
|
|
2022
Q3 | $4.58K | Sell |
313
-350
| -53% | -$6.06K | ﹤0.01% | 4261 |
|
|
2022
Q2 | $11.9K | Sell |
663
-1,226
| -65% | -$27.9K | ﹤0.01% | 3734 |
|
|
2022
Q1 | $56.3K | Sell |
1,889
-238
| -11% | -$7.61K | ﹤0.01% | 3532 |
|
|
2021
Q4 | $92.3K | Buy |
2,127
+1,563
| +277% | +$89.9K | ﹤0.01% | 3619 |
|
|
2021
Q3 | $40.1K | Buy |
564
+441
| +359% | +$40.5K | ﹤0.01% | 3560 |
|
|
2021
Q2 | $14.1K | Sell |
123
-330
| -73% | -$32.2K | ﹤0.01% | 3633 |
|
|
2021
Q1 | $47K | Sell |
453
-349
| -44% | -$33.1K | ﹤0.01% | 3625 |
|
|
2020
Q4 | $38.3K | Buy |
802
+28
| +4% | +$1.03K | ﹤0.01% | 3668 |
|
|
2020
Q3 | $21.5K | Buy |
774
+641
| +482% | +$18.4K | ﹤0.01% | 3814 |
|
|
2020
Q2 | $5.08K | Sell |
133
-203
| -60% | -$10.5K | ﹤0.01% | 3998 |
|
|
2020
Q1 | $16.5K | Buy |
336
+188
| +127% | +$9.22K | ﹤0.01% | 3947 |
|
|
2019
Q4 | $6.67K | Buy |
148
+95
| +179% | +$3.43K | ﹤0.01% | 4162 |
|
|
2019
Q3 | $2.22K | Buy |
53
+49
| +1,225% | +$1.93K | ﹤0.01% | 4350 |
|
|
2019
Q2 | $182 | Sell |
4
-4
| -50% | -$333 | ﹤0.01% | 4458 |
|
|
2019
Q1 | $620 | Hold |
8
| – | – | ﹤0.01% | 4170 |
|
|
2018
Q4 | $217 | Hold |
8
| – | – | ﹤0.01% | 4089 |
|
|
2018
Q3 | $392 | Hold |
8
| – | – | ﹤0.01% | 4352 |
|
|
2018
Q2 | $400 | Sell |
8
-34
| -81% | -$1.68K | ﹤0.01% | 4333 |
|
|
2018
Q1 | $1.75K | Buy |
42
+5
| +14% | +$330 | ﹤0.01% | 4101 |
|
|
2017
Q4 | $3.47K | Buy |
37
+19
| +106% | +$2.14K | ﹤0.01% | 4074 |
|
|
2017
Q3 | $2.65K | Sell |
18
-1
| -5% | -$105 | ﹤0.01% | 4043 |
|
|
2017
Q2 | $1.96K | Buy |
+19
| New | +$2.16K | ﹤0.01% | 4089 |
|
|
2016
Q2 | – | Sell |
-6
| Closed | -$544 | – | 3584 |
|
|
2016
Q1 | $544 | Buy |
+6
| New | +$531 | ﹤0.01% | 2551 |
|
Other funds holding IMDX
BC
AIC
PVI
VCM
HCM
FIA
VFT
BNP Paribas Financial Markets's IMDX Position: Q1 2026 in Review
BNP Paribas Financial Markets increased its Insight Molecular Diagnostics (IMDX) stake by 113% in Q1 2026, buying an estimated $197 and bringing the position to 64 shares worth $210. The position accounts for ﹤0.01% of the portfolio, ranked #5626.
BNP Paribas Financial Markets first reported a position in IMDX in Q1 2016 and has held it in 32 quarters since. The position peaked at $92.3K in Q4 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.
- BNP Paribas Financial Markets held 64 shares of Insight Molecular Diagnostics worth $210 as of Q1 2026.
- BNP Paribas Financial Markets bought 34 Insight Molecular Diagnostics shares in Q1 2026, an estimated $197.
- Insight Molecular Diagnostics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5626 holding.
- BNP Paribas Financial Markets first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 32 quarters since.
- BNP Paribas Financial Markets's Insight Molecular Diagnostics position peaked at $92.3K in Q4 2021.
- 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.